Related Experiment Videos
Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?
Insights
Carbonic anhydrase inhibitors, used for glaucoma, can cause serious lung issues in patients with chronic obstructive lung disease. Ophthalmologists must consider these pulmonary risks when prescribing these drugs.
Area of Science:
- Ophthalmology
- Pulmonology
- Pharmacology
Background:
- Carbonic anhydrase inhibitors are established treatments for glaucoma.
- These drugs have known side effects, but pulmonary risks are often overlooked.
- Chronic obstructive lung disease (COPD) and glaucoma are prevalent in the elderly population and frequently coexist.
Purpose of the Study:
- To review the physiological impact of carbonic anhydrase inhibition on carbon dioxide metabolism.
- To highlight the implications of these effects for patients with chronic lung disease.
- To emphasize the importance of pulmonary considerations for ophthalmologists.
Main Methods:
- Review of physiological effects of carbonic anhydrase inhibition.
- Analysis of implications for patients with chronic obstructive lung disease.
- Discussion of pulmonary complications associated with carbonic anhydrase inhibitors.
Main Results:
- Carbonic anhydrase inhibition affects carbon dioxide metabolism.
- Untoward pulmonary complications can arise in patients with chronic lung disease.
- These risks are particularly relevant due to the frequent co-occurrence of glaucoma and COPD in elderly patients.
Conclusions:
- Ophthalmologists must be aware of the potential pulmonary hazards of carbonic anhydrase inhibitors.
- Careful patient selection and monitoring are crucial for individuals with coexisting glaucoma and chronic lung disease.
- Further attention is needed regarding the pulmonary implications of these commonly prescribed medications.
Abstract:
Carbonic anhydrase inhibitors, of proven value in the longterm management of glaucoma, have a number of troublesome side effects, most of which are well-known. However, their potential hazards to patients with chronic obstructive lung disease have received little attention. The author reviews the physiological effects of carbonic anhydrase inhibition on carbon dioxide metabolism and the implications for the chronic lung patient. The untoward pulmonary complications associated with the use of carbonic anhydrase inhibitors are of particular importance to ophthalmologists, since chronic lung disease and glaucoma, both common disorders in the elderly, frequently coexist in the same patient.